Kwality Pharmaceuticals Ltd. Announces AGM, Reports Robust FY 2024-25 Growth
Kwality Pharmaceuticals Ltd. has announced its Annual General Meeting (AGM) scheduled for 09 September 2025. The company reported a revenue of 2370 crore and a net profit of almost 240 crore for FY 2024-25, reflecting a strong year-on-year growth. The company has a diverse portfolio of over 3,000 formulations and is present in over 80 countries. Kwality is focusing on high-value therapeutic areas, R&D-led product development, and expansion into highly regulated markets. The company is also in the process of obtaining DSIR approval and has a pipeline of peptide-based oncology products and complex generics. Kwality's biological erythropoietin is undergoing clinical trials and is expected to be commercialized within the ongoing financial year.
Key Highlights
- Kwality Pharmaceuticals Ltd. reported a revenue of 2370 crore and a net profit of almost 240 crore for FY 2024-25.
- The company has a diverse portfolio of over 3,000 formulations and is present in over 80 countries.
- Kwality is focusing on high-value therapeutic areas, R&D-led product development, and expansion into highly regulated markets.
- The company is in the process of obtaining DSIR approval and has a pipeline of peptide-based oncology products and complex generics.
- Kwality's biological erythropoietin is undergoing clinical trials and is expected to be commercialized within the ongoing financial year.